Last edition
News about "exclusive licensing agreement"
Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
Exclusive Licensing Agreement | 30/12/2025 | By News Bureau
Lupin and Valorum Enter into Licensing Agreement for Armlupeg in US
Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront licence fee and a royalty payment on net sales.
Exclusive Licensing Agreement | 05/12/2025 | By Dineshwori
Glenmark Secures China's Approval For RYALTRIS
Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.
Exclusive Licensing Agreement | 11/11/2025 | By Dineshwori | 158
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy